Ganaxolone
Brand names: Ztalmy · Active ingredient: Ganaxolone
In short: ZTALMY is indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older.
What is Ganaxolone used for?
ZTALMY is indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older.
Ganaxolone dosage
ZTALMY is administered by mouth three times daily and must be taken with food .
The recommended titration schedule and maintenance dosage are based on body weight for patients weighing 28 kg or less. Dosage recommendations for patients weighing 28 kg or less are included in Table 1, and dosage recommendations for patients weighing more than 28 kg are included in Table 2. Dosage should be increased based on tolerability no more frequently than every 7 days. Titration increments should not exceed those shown in Table 1 and Table 2.
Dosage | Total Daily Dose | Day
2 mg/kg three times daily | 6 mg/kg/day | 1 to 7
4 mg/kg three times daily | 12 mg/kg/day | 8 to 14
8 mg/kg three times daily | 24 mg/kg/day | 15 to 21
14 mg/kg three times daily | 42 mg/kg/day | 22 to 28
21 mg/kg three times daily | 63 mg/kg/day | 29 and thereafter
Dosage | Total Daily Dose | Day
50 mg three times daily | 150 mg | 1 to 7
100 mg three times daily | 300 mg | 8 to 14
200 mg three times daily | 600 mg | 15 to 21
400 mg three times daily | 1,200 mg | 22 to 28
600 mg three times daily | 1,800 mg | 29 and thereafter
See the Instructions for Use for complete instructions on how to properly prepare and administer ZTALMY.
Shake the bottle thoroughly for at least 1 minute and then wait for 1 minute before measuring and administering each dose.
Measure and administer the prescribed dose using the oral syringe(s) provided by your pharmacist. A household teaspoon or tablespoon is not an adequate measuring device and should not be used.
ZTALMY must be administered with food .
Discard any unused ZTALMY oral suspension after 30 days of first opening the bottle .
ZTALMY is administered by mouth three times daily and must be taken with food .
The recommended titration schedule and maintenance dosage are based on body weight for patients weighing 28 kg or less. Dosage recommendations for patients with severe hepatic impairment and weighing 28 kg or less are included in Table 3, and dosage recommendations for patients with severe hepatic impairment (Child-Pugh class C) weighing more than 28 kg are included in Table 4. Dosage should be increased based on tolerability no more frequently than every 7 days. Titration increments should not exceed those shown in Table 3 and Table 4.
No dosage adjustment is necessary in patients with mild (Child-Pugh class A) or moderate (Child-Pugh class B) hepatic impairment.
Dosage | Total Daily DoseApproximate daily dose. | Days
0.66 mg/kg three times daily | 2 mg/kg/day | 1 to 7
1.33 mg/kg three times daily | 4 mg/kg/day | 8 to 14
2.66 mg/kg three times daily | 8 mg/kg/day | 15 to 21
4.66 mg/kg three times daily | 14 mg/kg/day | 22 to 28
7 mg/kg three times daily | 21 mg/kg/day | 29 and thereafter
Dosage | Total Daily DoseApproximate daily dose. …
How to take Ganaxolone — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
Somnolence and Sedation
Caution patients about operating hazardous machinery, including motor vehicles, until they are reasonably certain that ZTALMY does not affect them adversely (e.g., impair judgment, thinking, or motor skills) .
Suicidal Thinking and Behavior
Counsel patients, their caregivers, and their families that antiepileptic drugs, including ZTALMY, may increase the risk of suicidal thoughts and behavior and advise them to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts of self-harm. Instruct patients, caregivers, and families to report behaviors of concern immediately to healthcare providers .
Withdrawal of Antiepileptic Drugs (AEDs)
Advise patients not to discontinue use of ZTALMY without consulting with their healthcare provider. ZTALMY should normally be gradually withdrawn to reduce the potential for increased seizure frequency and status epilepticus . …
Warnings & precautions
Do not take this medicine if: None.
ZTALMY can cause somnolence and sedation. In Study 1 , the incidence of somnolence and sedation was 44% in patients treated with ZTALMY, compared with 24% in patients receiving placebo. Somnolence and sedation appeared early during treatment and were generally dose-related .
Other central nervous system (CNS) depressants, including opioids, antidepressants, and alcohol, could potentiate somnolence and sedation in patients receiving ZTALMY . Prescribers should monitor patients for somnolence and sedation, and advise patients not to drive or operate machinery until they have gained sufficient experience on ZTALMY to gauge whether it adversely affects their ability to drive or operate machinery.
Antiepileptic drugs (AEDs), including ZTALMY, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with an AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior.
Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs, that did not include ZTALMY, showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. …
Ganaxolone side effects
The following important adverse reactions are described elsewhere in the labeling:
Somnolence and Sedation
Suicidal Behavior and Ideation
Withdrawal of Antiepileptic Drugs
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In controlled and uncontrolled trials in patients with seizures associated with CDD, 102 patients were treated with ZTALMY, including 83 patients treated for more than 6 months, and 50 patients treated for more than 1 year.
In Study 1, 50 patients received ZTALMY . The duration of treatment in this trial was up to 17 weeks. Approximately 78% of these patients were female, 92% were White, and the mean age was 6.8 years (range 2 to 19 years). All patients receiving ZTALMY, except 1, were taking other AEDs. Adverse reactions in these patients are presented below.
The most common adverse reactions (an incidence of at least 5% and at least twice the rate of placebo) were somnolence, pyrexia, salivary hypersecretion, and seasonal allergy (Table 6).
The adverse reactions leading to treatment discontinuation in ZTALMY-treated patients were somnolence and seizure (1 patient) and seizure (1 patient).
Twenty-two percent of ZTALMY-treated patients had dosing interrupted or reduced because of any adverse reaction, compared to 16% of placebo-treated patients. …
Drug interactions
Concomitant use of ZTALMY and UGT inhibitors (e.g., valproic acid) may increase the exposure of ganaxolone, which may increase the risk of ZTALMY associated adverse reactions in patients who have titrated to a stable ZTALMY dosage. Consider a reduction of ZTALMY maintenance dosage when initiating a UGT inhibitor .
Coadministration of ZTALMY with CYP450 inducers, such as strong or moderate CYP3A4 inducers, will decrease ganaxolone exposure, which can lower the efficacy of ZTALMY .
It is recommended to avoid concomitant use of strong or moderate CYP3A4 inducers with ZTALMY. When concomitant use of strong or moderate CYP3A4 inducers is unavoidable, consider an increase in the dosage of ZTALMY; however, do not exceed the maximum daily dosage of ZTALMY .
In patients on a stable ZTALMY dosage who are initiating or increasing the dosages of enzyme-inducing antiepileptic drugs (e.g., carbamazepine, phenytoin, phenobarbital, and primidone), the ZTALMY dosage may need to be increased; however, do not exceed the maximum daily dosage of ZTALMY .
Concomitant use of ZTALMY with CNS depressants, including alcohol, may increase the risk of somnolence and sedation .
About this medicine
ZTALMY (ganaxolone) oral suspension contains ganaxolone, a neuroactive steroid gamma-aminobutyric acid A (GABAA) receptor positive modulator. Ganaxolone (1-[(3R, 5S, 8R, 9S, 10S, 13S, 14S, 17S)-3-hydroxy-3, 10, 13-trimethyl-1, 2, 4, 5, 6, 7, 8, 9, 11, 12, 14, 15, 16, 17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone) is a methyl-substituted (at the 3β position) analog of the endogenous neurosteroid allopregnanolone, a derivative of progesterone. Its empirical formula is C22H36O2, and the molecular weight is 332.53 g/mol. The chemical structure is:
Ganaxolone is a white to off-white crystalline powder that only exists in one crystal form and has low aqueous solubility.
ZTALMY is an oral suspension of ganaxolone. Each mL of oral suspension contains 50 mg of ganaxolone. Inactive ingredients include artificial cherry flavor, citric acid, hypromellose, methylparaben, polyvinyl alcohol, propylparaben, purified water, simethicone emulsion, sodium benzoate, sodium citrate, sodium lauryl sulfate, and sucralose. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID d91612c4-b03a-4be4-a1ee-6a13e3b83d4e. Read the full official label on DailyMed.
Related medicines
Gabapentin Lamotrigine Pregabalin Topiramate Levetiracetam Oxcarbazepine Carbamazepine Ciclopirox